402 related articles for article (PubMed ID: 32462673)
21. Targeting the CALR interactome in myeloproliferative neoplasms.
Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
[TBL] [Abstract][Full Text] [Related]
22. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
23. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
[TBL] [Abstract][Full Text] [Related]
24. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
25. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
26. Calreticulin mutations in myeloproliferative neoplasms.
Shide K
Int Rev Cell Mol Biol; 2021; 365():179-226. PubMed ID: 34756244
[TBL] [Abstract][Full Text] [Related]
27. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
28. The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications.
Vainchenker W; Plo I; Marty C; Varghese LN; Constantinescu SN
Expert Rev Hematol; 2019 Jun; 12(6):437-448. PubMed ID: 31092065
[No Abstract] [Full Text] [Related]
29. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
30. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
[TBL] [Abstract][Full Text] [Related]
31. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
32. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
33. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
[TBL] [Abstract][Full Text] [Related]
34. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
35. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
36. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
37. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
38. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.
Papadopoulos N; Nédélec A; Derenne A; Şulea TA; Pecquet C; Chachoua I; Vertenoeil G; Tilmant T; Petrescu AJ; Mazzucchelli G; Iorga BI; Vertommen D; Constantinescu SN
Nat Commun; 2023 Apr; 14(1):1881. PubMed ID: 37019903
[TBL] [Abstract][Full Text] [Related]
40. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
